08 septiembre 2015

PM01183 Inicia una Nueva Fase I para : Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors en Santa Monica, California, United States .



Brief summary :


Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the PM01183 plasma concentration/QTc relationship, and to explore related ECG parameters in patients with selected solid tumors.


Recruitment Information :

Status : Recruiting
Start date : 2015-08
Primary completion date : 2016-06 (Anticipated) .


Administrative Data :

Organization name : PharmaMar
Organization study ID : PM1183-B-005-14-QT
Sponsor : PharmaMar
Health Authority United States : Food and Drug Administration .

...
en